PT2684955T - Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor - Google Patents

Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor

Info

Publication number
PT2684955T
PT2684955T PT131791444T PT13179144T PT2684955T PT 2684955 T PT2684955 T PT 2684955T PT 131791444 T PT131791444 T PT 131791444T PT 13179144 T PT13179144 T PT 13179144T PT 2684955 T PT2684955 T PT 2684955T
Authority
PT
Portugal
Prior art keywords
angiogenesis
vascularisation
inhibiting tumour
vessel repair
promoting
Prior art date
Application number
PT131791444T
Other languages
English (en)
Portuguese (pt)
Inventor
Zeiher Andreas
Dimmeler Stefanie
Bonauer Angelika
Urbich Carmen
Original Assignee
T2Cure Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T2Cure Gmbh filed Critical T2Cure Gmbh
Publication of PT2684955T publication Critical patent/PT2684955T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT131791444T 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor PT2684955T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102007052114A DE102007052114B4 (de) 2007-10-30 2007-10-30 Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Publications (1)

Publication Number Publication Date
PT2684955T true PT2684955T (pt) 2017-12-13

Family

ID=40375407

Family Applications (2)

Application Number Title Priority Date Filing Date
PT131791444T PT2684955T (pt) 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor
PT88442736T PT2217704T (pt) 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT88442736T PT2217704T (pt) 2007-10-30 2008-10-30 Método para promover a angiogénese, a vascularização ou reparação de vasos ou para inibir a angiogénese de tumor

Country Status (16)

Country Link
US (4) US8258113B2 (https=)
EP (3) EP2684955B1 (https=)
JP (4) JP5898843B2 (https=)
CA (1) CA2704290C (https=)
CY (2) CY1120360T1 (https=)
DE (1) DE102007052114B4 (https=)
DK (2) DK2217704T3 (https=)
ES (2) ES2618203T3 (https=)
HR (2) HRP20170346T1 (https=)
HU (2) HUE031559T2 (https=)
LT (2) LT2684955T (https=)
NO (1) NO2684955T3 (https=)
PL (2) PL2217704T3 (https=)
PT (2) PT2684955T (https=)
SI (2) SI2217704T1 (https=)
WO (1) WO2009056116A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030376A1 (it) 2003-07-31 2005-02-01 Univ Roma Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia.
US11660317B2 (en) 2004-11-08 2023-05-30 The Johns Hopkins University Compositions comprising cardiosphere-derived cells for use in cell therapy
EP3342415B1 (en) 2006-08-08 2022-01-26 Rheinische Friedrich-Wilhelms-Universität Bonn Structure and use of 5' phosphate oligonucleotides
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
EP2297323A1 (en) 2008-05-21 2011-03-23 Hartmann, Gunther 5' triphosphate oligonucleotide with blunt end and uses thereof
US9249392B2 (en) 2010-04-30 2016-02-02 Cedars-Sinai Medical Center Methods and compositions for maintaining genomic stability in cultured stem cells
US9845457B2 (en) 2010-04-30 2017-12-19 Cedars-Sinai Medical Center Maintenance of genomic stability in cultured stem cells
EP2638158A4 (en) * 2010-11-11 2015-07-15 Univ Miami COMPOSITIONS, CELLS, KITS AND METHODS FOR AUTOLOGOUS STEM CELL THERAPY
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
WO2013184527A1 (en) 2012-06-05 2013-12-12 Capricor, Inc. Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy
US9388408B2 (en) 2012-06-21 2016-07-12 MiRagen Therapeutics, Inc. Oligonucleotide-based inhibitors comprising locked nucleic acid motif
AU2013302799B2 (en) 2012-08-13 2018-03-01 Cedars-Sinai Medical Center Exosomes and micro-ribonucleic acids for tissue regeneration
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
ES2606636T3 (es) * 2013-01-24 2017-03-24 Pierre Fabre Médicament S.A.S. Composición que comprende un antagomir encapsulado
CA2902571A1 (en) 2013-03-15 2014-09-18 MiRagen Therapeutics, Inc. Bridged bicyclic nucleosides
US11253549B2 (en) 2014-05-23 2022-02-22 JangoBio, LLC Methods to rebalance the hypothalamic-pituitary-gonadal axis
US11439668B2 (en) 2014-05-23 2022-09-13 JangoBio, LLC Methods to differentiate stem cells into hormone-producing cells
CA2962444C (en) 2014-10-03 2023-09-05 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy
US20160122762A1 (en) * 2014-10-27 2016-05-05 University Of Iowa Research Foundation Methods of treating atherosclerosis
US9885042B2 (en) 2015-01-20 2018-02-06 MiRagen Therapeutics, Inc. miR-92 inhibitors and uses thereof
EP3402543B1 (en) 2016-01-11 2021-09-08 Cedars-Sinai Medical Center Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction
WO2017210652A1 (en) 2016-06-03 2017-12-07 Cedars-Sinai Medical Center Cdc-derived exosomes for treatment of ventricular tachyarrythmias
CN107586784B (zh) * 2016-07-08 2020-08-25 田小利 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用
US11541078B2 (en) 2016-09-20 2023-01-03 Cedars-Sinai Medical Center Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders
EP4699658A2 (en) 2017-04-19 2026-02-25 Cedars-Sinai Medical Center Methods and compositions for treating skeletal muscular dystrophy
US11660355B2 (en) 2017-12-20 2023-05-30 Cedars-Sinai Medical Center Engineered extracellular vesicles for enhanced tissue delivery
US12146137B2 (en) 2018-02-05 2024-11-19 Cedars-Sinai Medical Center Methods for therapeutic use of exosomes and Y-RNAS
JP7360170B2 (ja) * 2018-02-28 2023-10-12 国立大学法人 東京医科歯科大学 虚血病変部位特異的な遺伝子治療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683036B2 (en) * 2003-07-31 2010-03-23 Regulus Therapeutics Inc. Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
EP2290071B1 (en) * 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
WO2006133022A2 (en) * 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
CA2657030A1 (en) * 2006-07-13 2008-01-17 The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
US8466117B2 (en) * 2006-07-28 2013-06-18 The Johns Hopkins University Compositions and methods for modulating angiogenesis
WO2008070082A2 (en) * 2006-12-04 2008-06-12 The Johns Hopkins University Stem-progenitor cell specific micro-ribonucleic acids and uses thereof
WO2009004632A2 (en) * 2007-07-05 2009-01-08 Yeda Research And Development Co. Ltd. Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation
CN101802227B (zh) * 2007-07-18 2014-12-10 科罗拉多大学董事会法人团体 非衰竭与衰竭的人心脏中微小rna的差异表达
DE102007052114B4 (de) 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle

Also Published As

Publication number Publication date
EP2684955B1 (de) 2017-09-06
PL2217704T3 (pl) 2017-06-30
JP5898843B2 (ja) 2016-04-06
DK2217704T3 (en) 2017-03-13
LT2684955T (lt) 2017-12-27
JP2011500858A (ja) 2011-01-06
HRP20170346T1 (hr) 2017-04-21
SI2684955T1 (en) 2018-01-31
PT2217704T (pt) 2017-03-15
US9279123B2 (en) 2016-03-08
CA2704290A1 (en) 2009-05-07
DK2684955T3 (en) 2017-12-18
CY1120226T1 (el) 2018-12-12
CY1120360T1 (el) 2019-07-10
LT2217704T (lt) 2017-04-10
PL2684955T3 (pl) 2018-05-30
NO2684955T3 (https=) 2018-02-03
WO2009056116A1 (de) 2009-05-07
US9862949B2 (en) 2018-01-09
EP2684955A1 (de) 2014-01-15
JP2014196317A (ja) 2014-10-16
US8258113B2 (en) 2012-09-04
ES2618203T3 (es) 2017-06-21
US20160237433A1 (en) 2016-08-18
EP2217704A1 (de) 2010-08-18
ES2651287T3 (es) 2018-01-25
DE102007052114A1 (de) 2009-05-07
HUE037494T2 (hu) 2018-08-28
JP2018083817A (ja) 2018-05-31
JP2016199565A (ja) 2016-12-01
EP2684956B1 (de) 2017-08-23
DE102007052114B4 (de) 2011-01-05
HRP20171874T1 (hr) 2018-01-12
EP2684956A1 (de) 2014-01-15
EP2217704B1 (de) 2016-12-07
US20120322856A1 (en) 2012-12-20
HUE031559T2 (hu) 2017-07-28
US8912158B2 (en) 2014-12-16
CA2704290C (en) 2018-05-15
SI2217704T1 (sl) 2017-05-31
US20100324118A1 (en) 2010-12-23
US20150018407A1 (en) 2015-01-15

Similar Documents

Publication Publication Date Title
HRP20171874T1 (hr) Postupak za poticanje angiogeneze, vaskularizacije ili obnavljanje krvnih žila ili za inhibiciju angiogeneze tumora
AP2012006304A0 (en) Hydraulic apparatus.
AP3883A (en) Refrigeration apparatus.
AP2011006035A0 (en) Fluid treatment apparatus.
EG26645A (en) Generate the power of the gyroglider control devices and the method used
AP2011006010A0 (en) Conveyor apparatus.
AP2012006347A0 (en) Conveyor apparatus.
AP2012006064A0 (en) Compounds and methods for treating influenza.
IL206972B (en) Fracture repair device
MX289002B (es) Metodo para la fabricacion de polimeros.
AP2012006052A0 (en) Improved method for synthesizing pirfenidone.
ZA201107543B (en) Method for on-demand constraception
AP2012006277A0 (en) Method for treating androgen receptor positive cancers.
AP2011005857A0 (en) Tablets for combination therapy.
ZA201001584B (en) Quenching vessel
AP2012006099A0 (en) Torrefaction apparatus.
SI2281801T1 (sl) Postopek za pridobivanje 3,3-diphenilpropilamina
AP2012006279A0 (en) Method for treating waste.
AP2011005894A0 (en) 5-alkynyl-pyridines.
PL2484005T3 (pl) Sposób eksploatacji maszyny prądu stałego
AP2010005372A0 (en) Method for regulating agrobacterium-mediated transformation.
AP2011005932A0 (en) Pyrazinoisoquinoline Compounds.
EP2484633A4 (en) COMPOSITION CONTAINING METAL SALT, SUBSTRATE, AND PROCESS FOR PRODUCING THE SUBSTRATE
GB0908270D0 (en) Prognostic method
PT2509599E (pt) Processo para o tratamento de cancro pancreático